They recently found that about 20% of patients are not good candidates for 273.
That's not accurate. They found that 20% do not possess the WT S1R, but rather a variant; however, most of them still received some benefit... more so with higher dosage.
I'm pretty sure that what you are saying is not true. Anavex found that the mutant type of the Sr1 receptor had a lesser response to 2-73. However a lesser response in not nearly the same as no response which is what you are suggesting.
Missling stated that at the high dose the mutant type patients responded nearly as well as the wild type patients.
Your suggestion that selling 2-73 to those patients would be unethical is pure unadulterated BS.
News 
Market Data 
Discover 
AI
